Veeva Systems Inc. (VEEV)
VEEV Stock Slips Despite New Research Site Clinical Trial System
Veeva introduces a Research Site Clinical Trial Management System to streamline trial operations, enhance collaboration, and accelerate clinical research efficiency.
Wall Street Analysts Think Veeva (VEEV) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should Know
Veeva (VEEV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Veeva Systems Inc. (VEEV) Is a Trending Stock: Facts to Know Before Betting on It
Veeva (VEEV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Veeva Systems: Staying Buy Rated As VEEV Is Executing Well
I reaffirm my buy rating on Veeva Systems due to strong 4Q25 results, driven by R&D growth and positive Vault CRM adoption traction. VEEV's revenue grew 14% y/y to $721 million, beating expectations, with significant margin improvements and a strong balance sheet. Vault CRM added 20 new customers, with multiple top 20 pharma commitments expected in 2025, signaling positive transition progress.
Veeva (VEEV) Is Considered a Good Investment by Brokers: Is That True?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
Veeva Shares Advance on Revenue, AI Growth
Life-sciences focused cloud solutions provider Veeva Systems, Inc. (VEEV) is beating Big Money expectations.
Veeva (VEEV) Upgraded to Strong Buy: Here's Why
Veeva (VEEV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
VEEV Stock Gains Following Latest Availability of HCP Access Data
Veeva Systems aims to provide immediate value for commercial operations and data analytics teams via CRM Pulse, which provides quarterly HCP access data.
Why Veeva Systems Stock Is Surging Today
Shares of Veeva Systems (VEEV 9.05%) are posting big gains in Thursday's trading despite broader sell-offs for the tech sector. The life-sciences software company's stock was up 10.2% as of 12:30 p.m.
VEEV Stock Up as Q4 Earnings & Revenues Beat Estimates, Margin Rise
Veeva Systems' fiscal fourth-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.
